Hansoh Pharma's HS-20197 Cleared for Clinical Trials in Advanced Solid Tumors
核心洞察
Hansoh Pharma announced that its self-developed Class 1 injectable new drug HS-20197 (搜索) has received a Clinical Trial Approval Notice from China's National Medical Products Administration (搜索).
The approval covers clinical trials of HS-20197 (搜索) in patients with advanced solid tumors (搜索), according to a report from the Economic Information Agency.
HS-20197 (搜索) is an internally developed injectable candidate, and the NMPA clearance allows Hansoh Pharma to begin clinical evaluation in this tumor setting.
Hansoh Pharma has received a Clinical Trial Approval Notice from China's National Medical Products Administration (搜索) (NMPA) for its self-developed Class 1 injectable new drug HS-20197 (搜索). The clearance covers clinical trials in advanced solid tumors (搜索).
The company disclosed the approval on the 16th, according to a report from the Economic Information Agency. HS-20197 (搜索) is an internally developed injectable candidate.